ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589
Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.
Despite recent advances in our understanding disease process of PsA, and targeted therapies, further studies are needed to better understand PsA pathophysiology and to identify reliable disease biomarkers.
To help address this, Siebert, et al. evaluated gene expression in blood of patients with PsA versus healthy controls to help gain insights into the underlying biology of PsA and identify changes associated with guselkumab treatment.